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Abstract
 
Most approaches targeting the immune system against tumors have focused on patients with
established tumors. However, whether the immune system can recognize preneoplastic stages
of human cancer is not known. Here we show that patients with preneoplastic gammopathy
mount a vigorous T cell response to autologous premalignant cells. This preneoplasia-specific
CD4
 
 
 
 and CD8
 
 
 
 T cell response is detected in freshly isolated T cells from the BM. T cells
from myeloma marrow lack this tumor-specific rapid effector function. These data provide
direct evidence for tumor specific immune recognition in human preneoplasia and suggest a
possible role for the immune system in influencing the early growth of transformed cells, long
before the development of clinical cancer.
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Introduction
 
Up to 1–3% of elderly humans have clonal expansions of
transformed plasma cells called preneoplastic gammopa-
 
thy (MGUS) (1). Recent studies using interphase cyto-
genetics and gene expression profiling have shown that
transformed plasma cells in MGUS carry most of the
known cytogenetic and genomic changes found in its
malignant counterpart, multiple myeloma (2–4). Yet, the
great majority of MGUS patients remain stable for pro-
longed periods without ever developing clinical malig-
nancy (1). Whether the immune system can recognize
such clonally expanded preneoplastic cells in patients is
not known.
In prior studies, we found that freshly isolated T cells
from blood and marrow of patients with newly diagnosed
multiple myeloma (MM) do not exhibit detectable rapid
IFN-
 
 
 
 secretion in response to autologous tumor (5).
However, effector cells for viral pathogens were detected,
and tumor-reactive killer T cells could be expanded after 2
wk in vitro stimulation with autologous tumor-loaded DCs
(5). Here we show that patients with MGUS mount a
vigorous immune response to their preneoplastic cells,
which is readily detectable in T cells from the BM tumor
bed, without the need for prolonged in vitro expansion, as
in MM patients.
 
Materials and Methods
 
Isolation of Tumor and Immune Cells.
 
Concurrent peripheral
blood and BM samples were obtained from 12 patients with a
diagnosis of multiple myeloma (
 
n
 
 
 
  
 
6) or MGUS (
 
n
 
 
 
  
 
6) based
on standard criteria (6). All patients signed an informed consent
approved by the institutional review board.
Mononuclear cells from blood or BM were obtained by density
gradient centrifugation using Ficoll Hypaque. DCs were generated
from monocytes by culture of adherent blood mononuclear cells
in the presence of GM-CSF (Immunex) and IL-4 (R&D Systems)
as described (7). Nonadherent cells were used as a source of
blood T cells. BM mononuclear cells were separated into tumor/
 
preneoplastic (CD138 positive) and nontumor (CD138 negative)
fractions using CD138 magnetic beads using the manufacturer’s
protocol (Miltenyi Biotec) (5). Tumor/preneoplastic cells were
cryopreserved in aliquots for use as sources of antigen and targets.
Nontumor cell fractions were also cryopreserved for use as a
source of T cells from the marrow as described previously (5). In
some patients with IgG myeloma or MGUS, circulating Igs were
purified from plasma by affinity chromatography on a protein G
sepharose column (Amersham Biosciences) as described (5).
 
Generation of Antigen-loaded DCs.
 
Autologous tumor/preneo-
plastic cells were opsonized using anti–syndecan-1 antibody, 
 
 
 
irradiated, and then fed to immature DCs as described (5, 7). DCs
were then induced to mature by overnight culture in the presence
of a cytokine cocktail consisting of 10 ng/ml TNF-
 
 
 
 1, 10 ng/ml
 
IL-1
 
 
 
, IL-6 1,000 U/ml (all from R&D Systems) and PGE
 
2
 
 (1 
 
 
 
g/
ml; Amersham Biosciences). For some experiments, autologous
DCs were pulsed overnight with purified Ig as described (5).
 
ELISPOT Assay for Quantitation of Cytokine-producing T
Cells.
 
The presence of tumor/preneoplasia-reactive, IFN-
 
 
 
–
producing T cells in both blood and marrow T cells was quantified
both directly ex vivo and after in vitro stimulation with antigen-
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pulsed DCs using a 16 h ELISPOT assay as described (7). Briefly,
autologous T cells from blood or marrow were cocultured with
unpulsed DCs, or DCs loaded with autologous or allogeneic my-
eloma cells, at a T:APC ratio of 10:1. For some experiments, au-
tologous tumor/preneoplasia (CD138
 
 
 
) or nontumor cells
(CD138
 
 
 
) fraction from the BM were used as APCs. After 16 h,
the presence of antigen-specific IFN-
 
 
 
 spot-forming cells were
quantified as described (5, 7).
 
Flow Cytometric Assay for the Detection of Intracellular Cytokines.
 
Tumor antigen–reactive cells in freshly isolated blood or marrow
T cells were also analyzed by flow cytometry–based assay for the
detection of intracellular cytokines as described previously (8).
Briefly, blood or BM T cells were cultured for 12 h with autolo-
gous unpulsed mature DCs, or DCs loaded with autologous tu-
mor, or cag tumor cell line in the presence of 0.7 
 
 
 
g/ml of
Golgistop (from Cytofix/CytoPerm Plus kit; BD Biosciences).
Cells were then fixed and permeabilized in 100 
 
 
 
l cytofix/cyto-
perm solution using manufacturer’s directions and stained for in-
tracellular cytokines (IFN-
 
 
 
). Samples were analyzed on FACSort
or FACS Calibur (Becton Dickinson) instrument using CellQuest
software. Lymphocyte events collected were typically 1–3 
 
 
 
 10
 
5
 
events per sample.
 
Expansion of Tumor-reactive T Cells in Culture.
 
Antigen-loaded
(or unpulsed) mature DCs were cocultured with autologous T
cells (2 
 
 
 
 10
 
5
 
 cells/well) from either the marrow or blood as de-
scribed previously (5). After 12–16 d of culture, T cells from sev-
eral microcultures were pooled, and tumor antigen–reactive T
cells were assayed by ELISPOT assays for reactivity against autol-
ogous tumor/preneoplasia-loaded DCs as described earlier (5).
 
Statistical Analysis.
 
Data for immune response between two
groups were compared using the Mann Whitney test, and signifi-
cance set at P 
 
 
 
 0.05.
 
Results
 
To study the interactions of the immune system with
preneoplastic or neoplastic cells, we obtained paired
blood and BM specimens from 12 consecutively referred
patients with a diagnosis of MGUS (
 
n
 
 
 
  
 
6) or MM (
 
n
 
 
 
 
 
6) based on standard diagnostic criteria (6). MM patients
included those with both early (Durie-Salmon stage I/II;
 
n
 
 
 
  
 
2) or advanced (stage III; 
 
n
 
 
 
  
 
4) stage disease and
were studied before the initiation of any chemotherapy.
Freshly isolated T cells from either blood or BM of my-
eloma patients did not react detectably to autologous tu-
mor-loaded DCs in a effector assay measuring IFN-
 
 
 
 se-
cretion, consistent with findings in prior studies (5) (Fig.
1). In contrast, when MGUS patients were studied IFN-
 
 
 
–producing T cells in response to preneoplasia-pulsed
DCs were readily detected in freshly isolated T cells from
all patients, without the need for prolonged ex vivo ex-
pansion. Therefore, we refer to these cells as rapid effec-
tors to distinguish them from those that require 1–2 wk in
vitro culture. Preneoplasia/tumor-specific IFN-
 
 
 
 produc-
ers in the BM, as detected by the ELISPOT assay, were
significantly higher in MGUS relative to myeloma (mean
55 versus 1 IFN-
 
 
 
 producers/10
 
5
 
 cells in MGUS versus
MM, respectively; P 
 
  
 
0.002). This effector T cell re-
sponse in MGUS was significantly enriched in the mar-
row relative to the blood (mean 55 versus 7 IFN-
 
 
 
 pro-
 
ducers/10
 
5
 
 cells in the marrow versus blood, respectively;
P 
 
  
 
0.008). Therefore, the marrow but not the blood of
MGUS patients contains significant numbers of rapid ef-
fector T cells that are reacting to antigens from these pre-
neoplastic cells.
To further characterize the nature of IFN-
 
 
 
 producers in
response to autologous tumor cell–loaded DCs, we used
intracellular cytokine flow cytometry (Fig. 2). With this as-
say, the antitumor effector response in MGUS was detected
in both CD4
 
 
 
 and CD8
 
 
 
 T cells from the BM of three out
of three patients tested (Fig. 2 A). Consistent with this, the
ELISPOT reactivity could not be depleted by removing ei-
ther CD4
 
 
 
 or CD8
 
 
 
 population alone (not depicted).
Therefore, the preneoplasia-specific effector T cell re-
sponse in MGUS marrow consists of both CD4
 
 
 
 and
CD8
 
 
 
 T cells.
We next addressed the antigenic specificity of the T
cells in MGUS by testing myeloma cell lines and preneo-
plastic cells from other individuals with MGUS. How-
ever, there was no recognition of autologous DCs loaded
similarly with allogeneic MGUS tumor cells or cag my-
eloma cell line (shown previously to highly express sev-
eral shared cancer–testis antigens) (7), suggesting that the
antitumor immune response is largely directed against a
pattern of antigens specific to each individual patient’s tu-
mor (Fig. 2, A and B). Myeloma and MGUS cells secrete
a monoclonal Ig that can serve as a patient-specific tumor
antigen (9). However, in contrast to lymphomas it is
largely secreted as a soluble antigen, which can lead to the
deletion of Ig-reactive T cells (10). Preneoplasia-specific
effectors in the marrow did not recognize autologous
monoclonal Ig-loaded DCs, indicating that the effector T
cells detected in these assays were not directed against Ig-
derived determinants (Fig. 2 B). This is remarkably similar
to the findings on reactivity of tumor-specific T cells
expanded in culture from MM patients using tumor cell–
loaded DCs (5). Importantly, the immune T cells also rec-
ognized isolated fresh MGUS plasma cells but not non-
plasma cells from the BM in the two patients tested (Fig.
2 C). We also tested the ability of autologous preneoplas-
tic cell–loaded DCs to expand preneoplasia-specific T
Figure 1. Enrichment of preneoplasia-specific effectors in the BM of
MGUS patients. Freshly isolated blood or BM T cells from patients with
MGUS (n   6) or myeloma (n   6) were tested for the recognition of
autologous tumor/preneoplasia-loaded DCs (DC-Tum) or unpulsed DCs
(DC) in a 16-h ELISPOT assay for IFN- –producing cells. 
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cells in culture in two patients with MGUS. Preneoplasia-
specific T cells could be expanded in both patients, al-
though the degree of expansion was greater with BM T
cells (Fig. 3). Therefore, the BM of MGUS patients con-
tains effector T cells that are specific to a patient’s preneo-
plastic clonal expansion.
 
Discussion
 
To our knowledge, these data provide the first direct ev-
idence for the enrichment of active preneoplasia-specific
immune effectors at the site of the transformed cells in pa-
tients with a human nonviral preneoplastic state. Impor-
tantly, these effector T cells can be detected without the
need for prolonged (1–2 wk) in vitro expansion. Such
rapid effector function is not observed in T cells from the
tumor bed in the clinical cancer, multiple myeloma. Most
prior studies studying immune response to autologous tu-
mor in humans have focused on patients with clinical can-
cer and not preneoplastic states. Prior studies have shown
that tumor-specific T cells capable of reacting with autolo-
gous tumor cells or cell lines can be expanded from blood,
LNs, tumor bed, or BM of tumor-bearing patients (5, 11–
14). In certain situations, such as some of the patients with
paraneoplastic neuronal disorders, tumors may be some-
what indolent. However, whether T cells from these pa-
tients recognize autologous tumor is not known (15). De-
tection of tumor-specific effector function in cancer
patients is not common and generally requires in vitro
stimulation using cytokines and antigen-presenting cells
(16). However, whether the human immune system
mounts a specific response to early “premalignant” prolifer-
ations of transformed cells in patients, which can persist for
many years before the development of clinical malignancy,
is not known (16). This is particularly relevant, as recent
studies have shown that many of the genes conferring inva-
sive growth in human cancer are already active in the early
preinvasive stages (17, 18). Prior studies have documented
lymphocytic infiltration in preneoplastic lesions such as
dysplastic nevi (19). However the evaluation of specific an-
titumor immune recognition of these lesions has been diffi-
cult, due to the lack of access to adequate amounts of fresh
tumor and immune cells from the tumor bed. Patients with
MGUS represent a useful model in this regard. In MGUS,
both the preneoplastic and the surrounding immune cells
can be isolated without the need for prolonged in vitro cul-
ture or the generation of cell lines. These considerations
Figure 2. Characterization of preneoplasia-specific immune effectors in
the MGUS BM. (A) Preneoplasia-specific IFN- –producing T cells consist
of both CD4  and CD8  T cells. Freshly isolated blood or BM T cells
from a patient with MGUS were cultured for 12 h with autologous control
DCs, DCs loaded with autologous preneoplastic cells, and DCs loaded
with the cag myeloma cell line. IFN- –producing CD4  and CD8  T
cells were examined by intracellular cytokine flow cytometry. Percentages
refer to the proportion of CD4  or CD8  T cells producing IFN- . Data
are representative of similar findings on three patients. (B) Preneoplasia-
reactive effectors are mostly specific for antigens on autologous preneo-
plastic cells. BM T cells from a patient with MGUS were tested for the
recognition of autologous control DCs, DCs loaded with autologous pre-
neoplastic cells, cag myeloma cell line, preneoplastic cells from a different
MGUS patient (allo), or exposed to 10  g/ml tumor-derived Ig. IFN- –
producing cells were quantified by a 16-h ELISPOT assay. Data are
representative of similar experiments on two patients. (C) Recognition of
fresh autologous MGUS tumor cells by immune cells in the BM. Freshly
isolated blood or BM T cells from patients with MGUS or myeloma were
tested for the recognition of autologous tumor/preneoplasia-loaded DCs
(DC-Tum) or unpulsed DCs (DC), or tumor/preneoplasia (Tum;
CD138 ) or nontumor (NT; CD138 ) fractions from the BM in a 16 h
ELISPOT assay for IFN- –producing cells. Data on the recognition of
MGUS tumor cells are representative of findings from two patients.
Figure 3. Antipreneoplasia T cells from MGUS patients can be expanded
in vitro using autologous preneoplastic cell–loaded DCs. Blood or marrow
T cells from a patient with MGUS were cocultured with DCs loaded
with autologous MGUS tumor cells. Tumor antigen–specific T cells were
quantified by testing reactivity to autologous control DCs or tumor
loaded DCs using a 16-h IFN-  ELISPOT assay. Data shown are repre-
sentative of similar findings from two patients. 
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along with recent advances in DC biology (7) allowed us to
measure effector T cell function against preneoplastic cells
in MGUS.
The degree to which the antitumor immune response in
humans is directed against tumor-derived unique or shared
antigens is of central importance to tumor immunotherapy
(20). Our data suggest that in the early stages of preneoplas-
tic growth, when an active immune effector function in T
cells removed from the tumor bed is detectable, most of the
reactivity is against the pattern of antigens unique to each
patient’s preneoplastic cells, since the T cells did not recog-
nize DCs loaded with allogeneic MGUS cells, or cag my-
eloma cells (7) that express high levels of several shared
cancer–testis antigens. Recent studies by our group and
others have shown that T cells from myeloma patients ex-
panded in vitro using autologous tumor-loaded DCs have a
similar reactivity, mostly against antigens from uncultured
autologous tumors (5, 21). Limitations in cell numbers pre-
vented us from testing multiple allogeneic tumor targets or
cell lines. Therefore, more rigorous testing is required to
fully assess the degree to which target antigens are shared
between these patients. Clinical progression to myeloma is
associated with the loss of rapid tumor-specific effector
function in the tumor bed. This may be due to the lack of
optimal antigen presentation by resident DCs, induction of
suppressor T cells, or the presence of immune inhibitory
factors in the tumor microenvironment (16, 22).
Our finding that there is a vigorous preneoplasia-specific
effector T cell response in the MGUS marrow raises im-
portant questions about the potential impact of this im-
mune response on the preneoplastic cells, and perhaps
more importantly, their microenvironment (1). In princi-
ple, the immune system can mediate both tumor suppres-
sive and promoting effects in vivo (16). In addition to the
direct antitumor effects of T cells, IFN-
 
 
 
 produced by tu-
mor-specific effectors can also mediate the inhibition of
myeloma tumor growth by modulating IL-6 and STAT-3
signaling in tumor cells in vivo (23, 24). IFN-
 
 
 
 may also
mediate antimyeloma effects by inhibiting angiogenesis
(25) and osteoclastogenesis (26), both of which are ob-
served in MM but not MGUS. Recent studies from our
laboratory suggest that tumor progression in clinical my-
eloma is also associated with a functional defect in gly-
colipid-reactive NK T cells, suggesting a possible role for
these innate lymphocytes in the immune control of my-
eloma as well (8). Interestingly, tumor-reactive effector T
cell function is lost even in patients with early myeloma
wherein NK T cell function is well preserved (8), suggest-
ing that the loss of tumor-specific effector T cell function is
an earlier event during tumor progression.
However, interactions of tumor and immune cells is
complex, and under certain circumstances immune activa-
tion, particularly of CD4
 
 
 
 T cells in tumor bearing mice,
may be deleterious (27–29). Requirement for such “reverse
immune surveillance” has been well documented for the
growth of some germinal center–derived lymphomas in
mice (30). T cells have also been suggested to play an im-
portant role in both oncogene-driven and pristane oil–
 
induced plasmacytomagenesis in mice (31, 32). The ob-
served host response may therefore play a critical role in the
maintenance of MGUS clone in vivo. Transformation to
multiple myeloma may then depend on the acquired ability
of transformed cells to overcome dependence on paracrine
signals derived from this microenvironment modulated by
the host immune response.
Further studies are needed to more fully characterize the
clinical and biologic significance of the observed host re-
sponse to MGUS cells in patients. Therefore, we have re-
cently initiated a US national cooperative group effort un-
der the auspices of South West Oncology Group to
prospectively study these patients. Preliminary data from
this ongoing trial confirm the observations in this paper and
may allow correlations with clinical, cytogenetic, and ge-
nomic changes in the preneoplastic cells (unpublished
data). Most of the attention to date for harnessing the im-
mune system against human cancer has been for the ther-
apy as opposed to prevention of cancer. Our finding that
human immune system can mediate vigorous immune re-
sponse to antigens from preneoplastic cells suggests the
need to similarly study host response in other human pre-
neoplastic states. Harnessing the immune system for im-
mune prevention or delay of cancer may have a major im-
pact on reducing net cancer burden in humans as with
infectious diseases (33).
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